Results 111 to 120 of about 52,582 (257)
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff +3 more
wiley +1 more source
Cancer Science, EarlyView.UBE2C upregulates cellular CD147 and enhances its release into the tumor microenvironment both as soluble CD147 (sCD147) and packaged within tumor‐derived exosomes. These CD147‐bearing signals induce T‐cell exhaustion, marked by elevated CTLA‐4 expression and reduced secretion of effector cytokines (IFN‐γ, TNF‐α, TGF‐β), ultimately diminishing CD8+ T ...
Xuwei Hong +7 more
wiley +1 more source
Cancer Science, EarlyView.Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai +16 more
wiley +1 more source
Immunological Heterogeneity in Gastric Cancer: Context‐Dependent Role of CD8+ T Cells
Cancer Science, EarlyView.CD8+ T cell infiltration in gastric cancer shows subtype‐dependent prognostic and predictive significance across TCGA molecular subtypes. Its clinical value is context‐dependent and requires integrated immune profiling to guide modern chemoimmunotherapy strategies.
Xiaofei Sun +3 more
wiley +1 more source
Microsatellite instability in aborted embryos [PDF]
Molecular Human Reproduction, 1996 H, Kiaris +3 more
openaire +2 more sources
Colorectal cancers and microsatellite instability
Colorectal cancer (CRC) is a multifactorial disease arising from the complex interplay between genetic predisposition and environmental influences. Despite its widespread incidence globally, CRC demon strates favorable prognostic outcomes when detected at an early stage. Microsatellite instability (MSI) is a common molecular abnormality associated with
Esmkhani, Sahra +7 more
openaire +3 more sources
Cancer Science, EarlyView.AI‐based spatial analysis of tumor‐infiltrating lymphocytes in ovarian cancer revealed the highest infiltration in high‐grade serous carcinoma. Integrating pathology‐based immune phenotypes with HRD status provided additional prognostic insight and highlighted distinct relationships between TILs and genomic structure.
Kohei Hamada +17 more
wiley +1 more source
The Evolving Landscape of Rectal Cancer Management—A Case for Centralisation?
ANZ Journal of Surgery, EarlyView.
Rathin Gosavi +2 more
wiley +1 more source